Cozaar Indication:

For the treatment of hypertension.

Cozaar Mechanism Of Action:

Cozaar and its longer acting active metabolite (E-3174) interfere with the binding of angiotensin II to the angiotensin II AT1-receptor by, themselves, binding reversibly to the receptors in vascular smooth muscle and the adrenal gland. As angiotensin II is a vasoconstrictor, which also stimulates the synthesis and release of aldosterone, blockage of its effects results in decreases in systemic vascular resistance. Neither Cozaar or its metabolite inhibit the angiotensin converting enzyme, other hormone receptors, or ion channels.

Cozaar Drug Interactions:

Amiloride Increased risk of hyperkaliemia
Drospirenone Increased risk of hyperkaliemia
Potassium Increased risk of hyperkaliemia
Spironolactone Increased risk of hyperkaliemia
Triamterene Increased risk of hyperkaliemia
Indomethacin Indomethacin decreases the effect of losartan
Lithium Cozaar increases serum levels of lithium
Rifampin Rifampin decreases the effect of losartan

Cozaar Food Interactions:

Take without regard to meals. Take at same time each day. Food delays absorption, but does not affect the extent of absorption.

Cozaar Generic Name:

Synonyms:

  • Not Available

Drug Type:

Small Molecule; Approved

Absorption:

Well absorbed, the systemic bioavailability of losartan is approximately 33%

Toxicity (Overdose):

Hypotension and tachycardia; Bradycardia could occur from parasympathetic (vagal) stimulation, LD50= 1000 mg/kg (orally in rat)

Protein Binding:

99.7%

Biotransformation:

Hepatic. Oxidation of the 5-hydroxymethyl group on the imidazole ring results in the active metabolite of losartan.

Half Life:

2 hours

Dosage Forms of Cozaar:

Tablet Oral

Chemical IUPAC Name:

[2-butyl-5-chloro-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol

Organisms Affected:

Humans and other mammals

Cozaar to general, pharmacology

General, pharmacology..